Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Saturday's Exclusive News Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsBy Nathan Reiff. First Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicines market is projected to reach $366 billion over the next eight years. Companies often pursue niche strategies, developing therapies that target specific cancers with dedicated mechanisms. Fortunately, several promising treatments have shown notable potential—and with that comes the possibility of significant sales. Two smaller biotech companies are seeing meaningful share-price momentum thanks to their leading oncology medicines. Besides offering powerful clinical potential, these drugs could help the firms move beyond penny-stock (or otherwise unstable) status and toward long-term stability and profitability. That said, both companies face important challenges, making them typical high-risk biotech investments that could also generate outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, jumping nearly 37% in a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date (YTD) gains, with shares more than doubling this year. Still, with a consensus price target of $8.88, Wall Street expects more—the target implies roughly another 71% upside from current levels. The main catalyst for Iovance's move is its lead product, Amtagvi, a T-cell immunotherapy for certain melanomas. Amtagvi has been approved in the United States since 2024 and is gaining momentum in sales and regulatory progress, with additional approvals likely in the EU, U.K., and other regions. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales. Amtagvi's potential may extend beyond melanoma: the drug received FDA Fast Track designation for non-small cell lung cancer and is being evaluated for other indications. Some of Iovance's outperformance this year also follows its Q4 2025 earnings report issued in late February, in which the company reported a narrower-than-expected loss per share and $5 million in revenue. For the full year, revenue rose about 30% year-over-year. Iovance is still a small (~$2 billion) biotech and a penny-stock name; despite this year's rally, analysts remain cautious—about half of its roughly a dozen ratings are Hold or Sell. Risks are material: beyond the usual smaller-biotech concerns, Amtagvi is a personalized, costly, and complex therapy to manufacture, which could constrain margins and profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but despite that pullback its year-to-date performance far outpaces Iovance's. IBRX shares are up nearly 300% in 2026 so far, and analysts remain upbeat: the consensus price target is $13.60, roughly 70% above the current price even after the recent surge. ImmunityBio's primary growth driver is Anktiva, a treatment for certain bladder cancers. In February, shares jumped after the EU regulator granted the drug conditional marketing authorization—the latest in a string of approvals worldwide. Anktiva is already contributing materially to revenue, generating $113 million in sales last year, about a 700% year-over-year increase. As with Amtagvi, Anktiva is also being explored for additional cancer indications, which could further expand its market opportunity. Despite the dramatic run-up, IBRX remains a speculative, higher-risk investment. The company posted a sizable full-year net loss of $351 million for 2025 as R&D expenses continue to climb. Analysts appear slightly more bullish on ImmunityBio than on Iovance: six of seven covering the stock rate it a Buy or equivalent. | 
